CDMO : 세계 시장에서의 기회와 경쟁 환경

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

The global CDMO market for drug product/finished drug manufacturing services is expected to grow from $50.6 billion in 2024 to $69.7 billion by the end of 2029, at a CAGR of 6.6% from 2024 to 2029.

The global CDMO market for analytical testing and regulatory support services is expected to grow from $19.7 billion in 2024 to $29.9 billion by the end of 2029, at a CAGR of 8.7% from 2024 to 2029.

Report Scope

This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.

The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 76 data tables and 32 additional tables
• An overview of the global contract development and manufacturing organization (CDMO) market
• Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
• Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
• Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
• A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
• A discussion of the ESG challenges and practices in the CDMO industry
• An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
• Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Value Chain Analysis
• Small-Molecule Drugs
• Biologics
• Advanced Therapy Medical Products
• PESTEL Analysis of the Pharmaceutical Industry
• Political Factors
• Economic Factors
• Social Factors
• Technological Factors
• Environmental Factors
• Legal Factors

Chapter 3 Market Dynamics

• Global Market Dynamics
• Market Drivers
• Increase in Pharmaceutical Outsourcing Practices
• Pressure on R&D Spending
• Rising Demand for Advanced Therapeutics
• Upsurge in the Number of Clinical Trials
• Market Restraints
• Strict Regulations and Compliance Requirements
• Shortage of Skilled Technical Personnel
• Strong Competition in Cost, Technology and Service Ranges
• Market Opportunities
• Inorganic Growth

Chapter 4 Emerging Trends

• Overview
• Increased Focus on Biologics and Cell and Gene Therapy
• Integration of Digital Technologies
• Collaborative Risk Management

Chapter 5 Regulatory Landscape

• Overview
• Good Manufacturing Practice (GMP)
• Quality Assurance and Quality Control
• Regulatory Submissions
• Environmental & Safety Regulations
• International Standards
• Data Integrity & Security
• Labeling & Packaging
• Audits and Inspections

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Type of Service
• API Manufacturing Services
• Drug Product/Finished Drug Manufacturing Services
• Pharmaceutical Development Services
• Analytical Testing and Regulatory Support Services
• Market Breakdown by Type of Molecule
• Small-molecule Drugs
• Biologics
• Advanced Therapies
• Market Breakdown by End User
• Clinical
• Commercial
• Geographic Breakdown
• Market Breakdown by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Overview
• New Entrants in Market
• Global Market Shares of Leading Companies

Chapter 8 Sustainability in CDMO Market: ESG Perspective

• Overview
• Green Chemistry and Pharmaceutical Manufacturing
• Considering Sustainability through the Development Cycle and Across the Supply Chain
• Sustainability in the CDMO industry
• Environmental Considerations
• Social Considerations
• Governance Factors
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• CATALENT INC.
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• LONZA
• MERCK KGAA
• RECIPHARM AB
• SAMSUNG BIOLOGICS
• SIEGFRIED HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• WUXI APPTEC